We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms that ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $8.50, reflecting a +1.92% shift from the previouse trading day's closing. The stock outperformed the S&P 500, ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

EST Recursion Pharmaceuticals (RXRX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was the target of some unusual options trading on Thursday. Investors acquired 23,699 call options on the company. This is an increase ...

We recently published a list of 10 Firms Hit Hard in Thursday’s Trading. In this article, we are going to take a look at ...